In a recent European Society for Medical Oncology (ESMO) Congress, research teams reported preliminary results from clinical trials of three different PARP inhibitors in patients with ovarian cancer, including the PAOLA‐1/ENGOT‐OV25 Phase III trial where the combination of PARP‐inhibitor olaparib and bevacizumab was assessed for the first time as maintenance therapy following platinum‐based chemotherapy in the overall population regardless of the BRCA status.114, 115, 116. The gene discussed is PARP1; the disease is ovarian carcinoma.